$299 Million is the total value of Flagship Pioneering Inc.'s 5 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MCRB | SERES THERAPEUTICS INC | $203,433,000 | +41.9% | 12,682,876 | 0.0% | 68.04% | +34.6% | |
SYRS | Sell | SYROS PHARMACEUTICALS INC | $47,169,000 | -39.0% | 3,204,437 | -33.3% | 15.78% | -42.2% |
EDIT | Sell | EDITAS MEDICINE INC | $40,203,000 | -29.0% | 1,674,435 | -50.4% | 13.45% | -32.7% |
TTOO | T2 BIOSYSTEMS INC | $8,193,000 | +30.9% | 1,950,583 | 0.0% | 2.74% | +24.1% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-03
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
MODERNA INC | 20 | Q3 2023 | 76.9% |
EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
Axcella Health Inc | 17 | Q2 2023 | 3.5% |
KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
4 | 2024-02-14 |
13F-HR | 2023-11-14 |
4 | 2023-09-15 |
4 | 2023-08-15 |
13F-HR | 2023-08-14 |
4 | 2023-07-13 |
13F-HR | 2023-05-15 |
4 | 2023-02-27 |
13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.